Medscape Conference Coverage, based on selected sessions at the:

30th Annual San Antonio Breast Cancer Symposium (SABCS)

December 13 - 16, 2007; San Antonio, Texas

This activity is not sanctioned by, nor a part of, the San Antonio Breast Cancer Symposium.

Conference News

  • Alphavbeta6 Potential Target for Breast Cancers

    The epithelial-specific integrin alphavbeta6 is showing promise as a possible therapeutic target for poor-prognosis breast cancers.
  • Tamoxifen Benefit in Breast Cancer After 5 Years

    The largest trial to date testing adjuvant therapy in breast cancer has found that, contrary to National Cancer Institute recommendations, tamoxifen can likely be continued beyond 5 years.
  • Aromatase-Inhibitor-Induced Bone Loss

    With a different mechanism of action than current options, denosumab is showing promise for breast cancer patients with aromatase-inhibitor-induced bone loss.
  • Hypofractionated Whole-Breast Irradiation

    Researchers are encouraging broader use of hypofractionated irradiation in early breast cancer.

The materials presented here do not reflect the views of Medscape or the companies providing unrestricted educational grants. These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. All readers or continuing education participants should verify all information and data before treating patients or employing any therapies described in this educational activity.

The materials presented here were prepared by independent authors under the editorial supervision of Medscape and do not represent a publication of the San Antonio Breast Cancer Symposium. These materials and the related activity are not sanctioned by the San Antonio Breast Cancer Symposium or the commercial supporter of the conference and do not constitute an official part of that conference.